| Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa S Eichstadt, M Barriga, A Ponakala, C Teng, NT Nguyen, Z Siprashvili, ... JCI insight 4 (19), 2019 | 91 | 2019 |
| CRIg mediates early Kupffer cell responses to adenovirus JQ He, KJ Katschke, P Gribling, E Suto, WP Lee, L Diehl, ... Journal of leukocyte biology 93 (2), 301-306, 2013 | 50 | 2013 |
| The C. elegans Rab Family: Identification, Classification and Toolkit Construction ME Gallegos, S Balakrishnan, P Chandramouli, S Arora, A Azameera, ... PloS one 7 (11), e49387, 2012 | 36 | 2012 |
| 304 Type VII collagen NC2 domain expression differentiates severe from milder recessive dystrophic epidermolysis bullosa subtypes A Ponakala, VK Yenamandra, CE Teng, M Barriga, J Dolorito, E Gorell, ... Journal of Investigative Dermatology 140 (7), S37, 2020 | | 2020 |
| PHASE 1/2A CLINICAL TRIAL OF GENE-CORRECTED AUTOLOGOUS CELL THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA E Gorell, S Eichstadt, M Barriga, A Ponakala, C Teng, N Nguyen, ... ACTA DERMATO-VENEREOLOGICA 100, 75-75, 2020 | | 2020 |
| 384 First in human use of a novel in vivo gene therapy to successfully correct recessive dystrophic epidermolysis bullosa (RDEB) skin: Results of a phase 1/2 placebo controlled … MP Marinkovich, K Sridhar, I Gurevich, A Ponakala, S Boddu, D Keene, ... Journal of Investigative Dermatology 139 (5), S66, 2019 | | 2019 |
| Role of CRIg on Kuppfer Cells in the Uptake of Adenovirus and Innnate Immune Responses A Ponakala California State University, East Bay, 2011 | | 2011 |
